Skip to main content

NASDAQ:ETTX - Entasis Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 257.14 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$1.96
▲ +0.07 (3.70%)
1 month | 3 months | 12 months
Get New Entasis Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.00
▲ +257.14% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 257.14% upside from the last price of $1.96.

Buy

The current consensus among 7 contributing investment analysts is to buy stock in Entasis Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2020Alliance Global PartnersInitiated CoverageBuyLow
i
9/8/2020Cantor FitzgeraldInitiated CoverageOverweight$5.00Low
i
Rating by L. Chen at Cantor Fitzgerald
8/7/2020HC WainwrightReiterated RatingBuy$5.00Medium
i
7/13/2020Roth CapitalInitiated CoverageBuy$9.00Medium
i
Rating by J. Aschoff at Roth Capital
6/21/2020CSFBReiterated RatingOutperform$8.00Low
i
6/21/2020WedbushReiterated RatingOutperform$7.00Low
i
6/21/2020Credit Suisse GroupReiterated RatingOutperform$8.00Low
i
5/8/2020BMO Capital MarketsLower Price TargetOutperform$15.00 ➝ $5.00High
i
4/14/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $5.00High
i
3/12/2020CSFBLower Price TargetOutperform$18.00 ➝ $14.00Low
i
3/12/2020Credit Suisse GroupLower Price TargetOutperform$18.00 ➝ $14.00Medium
i
3/12/2020HC WainwrightReiterated RatingBuyHigh
i
11/18/2019WedbushReiterated RatingOutperformMedium
i
Rating by R. Driscoll at Wedbush
8/19/2019HC WainwrightInitiated CoverageBuy$18.00Low
i
Rating by E. Arce at HC Wainwright
4/2/2019WedbushReiterated RatingOutperform$19.00 ➝ $19.00High
i
Rating by R. Driscoll at Wedbush
10/24/2018SunTrust BanksInitiated CoverageBuy$20.00High
i
10/22/2018Credit Suisse GroupInitiated CoverageOutperform$18.00Low
i
10/22/2018WedbushInitiated CoverageOutperform$19.00Medium
i
Rating by R. Driscoll at Wedbush
10/22/2018BMO Capital MarketsInitiated CoverageOutperform$18.00Medium
i
(Data available from 5/16/2016 forward)
Entasis Therapeutics logo
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $1.96
$1.87
$1.97

50 Day Range

MA: $2.01
$1.82
$2.22

52 Week Range

Now: $1.96
$1.58
$4.25

Volume

292,190 shs

Average Volume

354,647 shs

Market Capitalization

$73.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Entasis Therapeutics?

The following Wall Street sell-side analysts have issued reports on Entasis Therapeutics in the last twelve months: Alliance Global Partners, Cantor Fitzgerald, Credit Suisse Group AG, CSFB, HC Wainwright, Roth Capital, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ETTX.

What is the current price target for Entasis Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Entasis Therapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 257.1%. Roth Capital has the highest price target set, predicting ETTX will reach $9.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $5.00 for Entasis Therapeutics in the next year.
View the latest price targets for ETTX.

What is the current consensus analyst rating for Entasis Therapeutics?

Entasis Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ETTX will outperform the market and that investors should add to their positions of Entasis Therapeutics.
View the latest ratings for ETTX.

What other companies compete with Entasis Therapeutics?

How do I contact Entasis Therapeutics' investor relations team?

Entasis Therapeutics' physical mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company's listed phone number is (781) 810-0120 and its investor relations email address is [email protected] The official website for Entasis Therapeutics is www.entasistx.com.